Vilacto Bio Expands Its Exposure In Asia

Published: Jul 31, 2017

COPENHAGEN, Denmark, July 28, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI), will present at the China (Wuxi) International INDUSTRIAL DESIGN EXPO 2017, which is being held on September 21-24, 2017 at the Wuxi region, one of mainland China’s most innovative cities, organized by the Department of Science & Technology.

Vilacto Bio is there to expand its exposure in Asia, meeting with partners, distributors and investors.

Key meetings are expected to be held with Pharma companies that have shown an interest in the Lactoactive® molecule.

Vilacto Bio expects to start its fundraising efforts in Q4 to raise +5 m USD.

"This is another important step in our evolution as a public company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.

About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Vilacto Bio Inc.
The Seagram Building 
375 Park Avenue, Suite 2607 
New York City, NY 10152

Gert Andersen
Phone: +1 646-893-7895

Back to news